MedTrace Logo

Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics

NCT02169323 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-05-11

No results posted yet for this study

Summary

There is growing evidence that non-eosinophilic asthmatics are less sensitive to inhaled corticosteroids (ICS) than eosinophilic asthmatics.

As non-eosinophilic asthmatic patients are treated by ICS according to international guidelines for asthma, the investigators would like to investigate whether stepping-down of ICS in these patients may be safe. Indeed, the investigators can reasonably expect that a progressive cessation of ICS is possible in some of these patients without any clinical worsening.

Conditions

Interventions

OTHER

Step-down

Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months

Sponsors & Collaborators

  • Renaud Louis

    lead OTHER

Principal Investigators

  • Renaud Louis, MD-PhD · University of Liege

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-02-27
Completion
2017-02-27

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02169323 on ClinicalTrials.gov